Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
about
Lost in Translation (LiT): IUPHAR Review 6Primary medication non-adherence: analysis of 195,930 electronic prescriptionsAssociation between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerManagement of hot flashes in women with breast cancerOveractive bladder: strategies to ensure treatment compliance and adherenceFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewThe rational patient and beyond: implications for treatment adherence in people with psychiatric disabilitiesThe impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemicDepression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysisRacial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic reviewOral antineoplastic agents: how do we care about adherence?Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysisEndocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part DDeciphering the divergent roles of progestogens in breast cancer.Adjuvant therapy use among Appalachian breast cancer survivorsPredicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitorsA randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancerRacial disparities in initiation of adjuvant endocrine therapy of early breast cancer.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.The use of erlotinib in daily practice: a study on adherence and patients' experiences.Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerA population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioEndocrine Therapy - What Else?Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsTamoxifen and CYP2D6: a contradiction of data.Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsExtended release drug delivery strategies in psychiatry: theory to practiceCognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.
P2860
Q24289150-B8067BE5-A927-4590-B145-2BAF17039E00Q24619145-30051986-67E7-4887-B784-923455BEA12FQ24632347-C22415D3-4F11-4338-BF6D-92A818E0203FQ24644229-2C1256FB-2142-4E84-8D9E-347460915FDBQ26746914-439D3435-50FD-40E9-A329-832592D4D9DAQ26850736-A8D0C96D-A4BC-4699-B08B-70F971A6D54CQ26864657-9E98B95E-CB3D-411B-AF51-0A7DCC1418E5Q27021293-10BA8D5C-0497-49AF-AD42-C317A6BE7042Q27023110-59C3ACCE-B0EB-449E-80E5-0B22A21A471FQ28082674-B837486A-7122-49E6-B656-83E5BF3EFD55Q28082909-17D884C4-5955-43BE-912E-769ABBA1A4D4Q28087204-3320945C-361B-4A9F-A83E-C5696A268D49Q28657951-78CB8852-9A61-41ED-AA86-A0372FB7EB57Q30240711-A4EDC94F-329D-44B6-B7F6-75B709B8B3BCQ30279083-F1F02519-3CF7-4857-A17E-0137F4831D6EQ33562869-9F70E91C-B314-47DC-BDD2-F94EF2AB7769Q33603379-DE483C09-A812-43A9-97BF-ADAD1C2D6DFFQ33618145-AD139E80-CB4E-45F1-BB7A-8210ADD430E0Q33631047-EF68B4AE-BD12-4184-8302-497AF683E6D8Q33698446-0F6D3C3B-BFDA-4094-AE43-B88A13727202Q33756382-4E7D9E24-6DAD-4527-931B-438C784487C6Q33756969-F10DA8D3-13ED-4C25-A55D-ED5C339C030FQ33795923-669D23D2-F467-4F00-8CFF-DF4FC55A2AEDQ33818100-F426D2A7-9CDF-4AB5-A511-25ED3E043A9CQ33857602-C2477F6F-A411-4416-89E9-96B4DF4278DEQ33874887-EF90AB24-C2E4-4E11-8702-D1A1CBEF37B0Q33877830-2EF2B180-27BE-4CA0-8603-7F38E8389F3FQ33885999-C1873807-0394-4686-BEAA-5EDDA045063AQ33897610-0331993B-6008-4E44-8213-A8C8B4B2A403Q33927985-9A1174D6-00FE-401D-B8AC-2FA0453C5805Q33948681-8E58EC46-2D5F-4D29-99F8-718885720894Q33965106-6589BC85-A8FE-47DB-AAAD-CDCBD2E006A3Q33996270-86F5DA3B-91F5-4F89-9329-C5E0AC8F3BA0Q34095816-D01270F9-DC39-461E-B36E-E8E2B077EABBQ34096265-0344F91C-6050-4DAC-A1AC-4B5AD421CABAQ34193946-047CE86F-3209-42C2-BDEC-E0DFE36C66D6Q34244463-8A1969E5-0613-4603-9CB1-3FE3C89D3AACQ34346501-8C51145D-6A8B-4ED3-BE3C-4E6788775C93Q34396625-36F5B700-66A8-4A6E-B45B-10FF2212840AQ34402534-F6D0C50C-5367-4829-9FA8-D6143A0D84CC
P2860
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@en
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@nl
type
label
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@en
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@nl
prefLabel
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@en
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@nl
P2093
P356
P1476
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
@en
P2093
Ann H Partridge
Eric P Winer
Jerry Avorn
Philip S Wang
P304
P356
10.1200/JCO.2003.07.071
P407
P577
2003-02-01T00:00:00Z